XML 21 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Income Statement - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Income Statement [Abstract]      
Net Sales [1] $ 20,431 $ 20,175 $ 19,440
Cost of products sold 13,399 13,956 13,452
Gross Profit 7,032 6,219 5,988
Marketing, research and general expenses 3,961 3,581 3,399
Other (income) and expense, net [2],[3] 69 (43) 28
Operating Profit [3] 2,344 2,681 2,561
Nonoperating expense (96) (73) (86)
Interest income 66 14 6
Interest expense (293) (282) (256)
Income Before Income Taxes and Equity Interests 2,021 2,340 2,225
Provision for income taxes (453) (495) (479)
Income Before Equity Interests 1,568 1,845 1,746
Share of net income of equity companies 196 116 98
Net income 1,764 1,961 1,844
Net income attributable to noncontrolling interests 0 (27) (30)
Net Income Attributable to Kimberly-Clark Corporation $ 1,764 $ 1,934 $ 1,814
Earnings Per Share [Abstract]      
Basic $ 5.22 $ 5.73 $ 5.38
Diluted $ 5.21 $ 5.72 $ 5.35
Impairment of Intangible Assets (Excluding Goodwill) $ 658 $ 0 $ 0
[1] Net sales in the U.S. to third parties totaled $10,362, $9,848 and $9,285 in 2023, 2022 and 2021, respectively. No other individual country's net sales exceeds 10 percent of total net sales.
[2] Other (income) and expense, net in 2023 includes the gain of $74 related to the sale of our Brazil tissue and K-C Professional business, and in 2022 includes the non-cash, non-recurring gain of $85 related to the acquisition of a controlling interest in Thinx.
[3] Segment operating profit excludes Other (income) and expense, net and income and expenses not associated with the business segments.